SCHEMBL1939342

SCHEMBL1939342

CCOC(=O)c1c(C)nc(SC)nc1Nc1cccc(C)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.55
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
MAPT P10636 9/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
TP53 P04637 4/20 0.53
LMNA P02545 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46
CFTR P13569 1/20 0.45
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
POLB P06746 1/20 0.43
PPARG P37231 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1988610 0.90 LMNA (0.48) SYKMAPK1HTTMAPTL3MBTL1
SCHEMBL16964287 0.86 SYK (0.51) SYKMAPK1HTTMAPTL3MBTL1
SCHEMBL1298740 0.86 TP53 (0.56) SYKMAPK1HTTMAPTL3MBTL1
SCHEMBL1939779 0.85 LMNA (0.53) SYKMAPK1HTTMAPTL3MBTL1
SCHEMBL1949965 0.84 LMNA (0.49) SYKTP53LMNARXFP1SMN1; SMN2
SCHEMBL18351982 0.83 SYK (0.48) SYKMAPK1HTTMAPTL3MBTL1
SCHEMBL12103416 0.83 MAPT (0.43) SYKMAPK1HTTMAPTTP53
SCHEMBL19245828 0.81 ALOX5 (0.51) SYKMAPK1HTTMAPTLMNA
SCHEMBL12103792 0.81 MAPK1 (0.43) SYKMAPK1HTTMAPTL3MBTL1
SCHEMBL1298459 0.81 MAPT (0.44) SYKMAPK1HTTMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900639-B1 BICYCLIC DIHYDROPYRIDONE KINASE INHIBITORS PORTOLA PHARM INC (US) 2017-08-16 EP disclosed
EP-2900639-B1 BICYCLIC DIHYDROPYRIDONE KINASE INHIBITORS PORTOLA PHARM INC (US) 2017-08-16 EP disclosed
US-9533986-B2 Bicyclic dihydropyridone kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-01-03 US disclosed
US-9533986-B2 Bicyclic dihydropyridone kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-01-03 US disclosed
US-20150266871-A1 BICYCLIC DIHYDROPYRIDONE KINASE INHIBITORS ALEXION PHARMACEUTICALS, INC. 2015-09-24 US disclosed
EP-2900639-A1 BICYCLIC DIHYDROPYRIDONE KINASE INHIBITORS Portola Pharmaceuticals, Inc. (US) 2015-08-05 EP disclosed
EP-2330909-B1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2013-09-18 EP disclosed
US-8383635-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2013-02-26 US disclosed
US-8383635-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2013-02-26 US disclosed
US-8383635-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2013-02-26 US disclosed
EP-2330909-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2011-06-15 EP disclosed
US-20110136838-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2011-06-09 US disclosed
US-20110136838-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2011-06-09 US disclosed
US-20110136838-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2011-06-09 US disclosed
WO-2010019637-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2010-02-18 WO disclosed
WO-2010019637-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266871-A1 BICYCLIC DIHYDROPYRIDONE KINASE INHIBITORS SYK, JAK2, ZAP70 SYK 1/4885MAPK1 512/4885HTT 2725/4885
US-20110136838-A1 CHEMICAL COMPOUNDS PDK1, PDK4, PDK3 SYK 1481/4885MAPK1 201/4885HTT 2920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.